Post by Novotech

Early-phase trials are becoming much more than a first step in development. Increasingly, they’re where some of the most important strategic decisions get made. Read our latest blog on this topic: https://lnkd.in/g93QiJua In this new perspective, Novotech experts Daniela Caiazza, PhD, Vice President, Clinical Services and General Manager, ANZ, Alexander Lai, MD, PhD, Senior Principal Consultant, End-to-End Drug Development, Carolyn Luscombe, PhD, Manager, Therapeutic Strategy, Early Phase, Julie Gargano, Senior Director Site Engagement & Feasibility and Karen Scalzo-Inguanti PhD, Director, Drug Development Consulting and Early Phase Specialist explore how Phase I and early Phase II studies are evolving as sponsors look for earlier proof-of-concept and evidence that can support global development decisions. The article looks at: 🔹How biomarkers are changing the way early efficacy is assessed 🔹Why dose optimization now plays a bigger strategic role 🔹The impact operational execution can have on evidence quality 🔹How Australia can support faster, decision-ready early development #ClinicalTrials #EarlyPhase #DrugDevelopment